
Stephen C. Buczinski
Examiner (ID: 6852)
| Most Active Art Unit | 2202 |
| Art Unit(s) | 3642, 2603, 2507, 2200, 3202, 2103, 2202, 3662 |
| Total Applications | 1988 |
| Issued Applications | 1721 |
| Pending Applications | 62 |
| Abandoned Applications | 204 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17946076
[patent_doc_number] => 20220333093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => SITE-SPECIFIC CONJUGATION TO ANTIBODY LYSINE RESIDUES WITH SOLID-PHASE IMMOBILIZED MICROBIAL TRANSGLUTAMINASE MTG AND MTG IN SOLUTION
[patent_app_type] => utility
[patent_app_number] => 17/704960
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4577
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17704960
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/704960 | SITE-SPECIFIC CONJUGATION TO ANTIBODY LYSINE RESIDUES WITH SOLID-PHASE IMMOBILIZED MICROBIAL TRANSGLUTAMINASE MTG AND MTG IN SOLUTION | Mar 24, 2022 | Abandoned |
Array
(
[id] => 17836466
[patent_doc_number] => 20220273771
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES
[patent_app_type] => utility
[patent_app_number] => 17/697646
[patent_app_country] => US
[patent_app_date] => 2022-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16688
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697646
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/697646 | SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES | Mar 16, 2022 | Abandoned |
Array
(
[id] => 19186288
[patent_doc_number] => 20240165201
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUNE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/281927
[patent_app_country] => US
[patent_app_date] => 2022-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10512
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18281927
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/281927 | GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUNE DISORDERS | Mar 14, 2022 | Pending |
Array
(
[id] => 17828459
[patent_doc_number] => 20220265763
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/689631
[patent_app_country] => US
[patent_app_date] => 2022-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13733
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17689631
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/689631 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | Mar 7, 2022 | Abandoned |
Array
(
[id] => 19201476
[patent_doc_number] => 20240173375
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO
[patent_app_type] => utility
[patent_app_number] => 18/548845
[patent_app_country] => US
[patent_app_date] => 2022-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26441
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18548845
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/548845 | CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO | Mar 1, 2022 | Pending |
Array
(
[id] => 18003537
[patent_doc_number] => 20220362303
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => STABILIZED COLOSTRUM COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/681166
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30398
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681166
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/681166 | STABILIZED COLOSTRUM COMPOSITIONS | Feb 24, 2022 | Abandoned |
Array
(
[id] => 19256332
[patent_doc_number] => 12016356
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-25
[patent_title] => Sweet protein from truffle
[patent_app_type] => utility
[patent_app_number] => 17/680818
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 27431
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 196
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680818
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680818 | Sweet protein from truffle | Feb 24, 2022 | Issued |
Array
(
[id] => 17837724
[patent_doc_number] => 20220275029
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/673603
[patent_app_country] => US
[patent_app_date] => 2022-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38801
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673603
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/673603 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | Feb 15, 2022 | Abandoned |
Array
(
[id] => 18405803
[patent_doc_number] => 20230167154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/582368
[patent_app_country] => US
[patent_app_date] => 2022-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38037
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17582368
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/582368 | Melanocortin 1 receptor ligands and methods of use | Jan 23, 2022 | Issued |
Array
(
[id] => 17563156
[patent_doc_number] => 20220127305
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => MELANOCORTIN RECEPTOR LIGANDS
[patent_app_type] => utility
[patent_app_number] => 17/572115
[patent_app_country] => US
[patent_app_date] => 2022-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15788
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -218
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17572115
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/572115 | MELANOCORTIN RECEPTOR LIGANDS | Jan 9, 2022 | Abandoned |
Array
(
[id] => 19164770
[patent_doc_number] => 11980652
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Compositions and methods for subcutaneous administration of cancer immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/568251
[patent_app_country] => US
[patent_app_date] => 2022-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 18
[patent_no_of_words] => 26294
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17568251
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/568251 | Compositions and methods for subcutaneous administration of cancer immunotherapy | Jan 3, 2022 | Issued |
Array
(
[id] => 17749664
[patent_doc_number] => 20220227868
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/568281
[patent_app_country] => US
[patent_app_date] => 2022-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17568281
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/568281 | Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors | Jan 3, 2022 | Issued |
Array
(
[id] => 19050858
[patent_doc_number] => 20240092827
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => PROCESS FOR MANUFACTURING PEPTIDE
[patent_app_type] => utility
[patent_app_number] => 18/270509
[patent_app_country] => US
[patent_app_date] => 2021-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12982
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 293
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270509
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/270509 | Process for manufacturing peptide | Dec 28, 2021 | Issued |
Array
(
[id] => 17546714
[patent_doc_number] => 20220118055
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => RELEASABLE GLP-1 CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/559692
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30136
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559692
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/559692 | Releasable GLP-1 conjugates | Dec 21, 2021 | Issued |
Array
(
[id] => 17685889
[patent_doc_number] => 20220193181
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => S-NITROSOGLUTATHIONE (GSNO) AND GSNO REDUCATASE INHIBITORS FOR USE IN THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/557628
[patent_app_country] => US
[patent_app_date] => 2021-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9869
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17557628
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/557628 | S-NITROSOGLUTATHIONE (GSNO) AND GSNO REDUCATASE INHIBITORS FOR USE IN THERAPY | Dec 20, 2021 | Abandoned |
Array
(
[id] => 18034711
[patent_doc_number] => 20220378926
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => PSMA TARGETED CONJUGATE COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/555958
[patent_app_country] => US
[patent_app_date] => 2021-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17555958
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/555958 | PSMA targeted conjugate compounds and uses thereof | Dec 19, 2021 | Issued |
Array
(
[id] => 19624120
[patent_doc_number] => 12162924
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-10
[patent_title] => Method for the design of fibrillar collagen-mimetic peptide self-assemblies
[patent_app_type] => utility
[patent_app_number] => 17/554650
[patent_app_country] => US
[patent_app_date] => 2021-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 34
[patent_no_of_words] => 15492
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554650
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/554650 | Method for the design of fibrillar collagen-mimetic peptide self-assemblies | Dec 16, 2021 | Issued |
Array
(
[id] => 19273262
[patent_doc_number] => 12023369
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism
[patent_app_type] => utility
[patent_app_number] => 17/552499
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 3
[patent_no_of_words] => 3764
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552499
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/552499 | Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism | Dec 15, 2021 | Issued |
Array
(
[id] => 18921421
[patent_doc_number] => 20240024425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => PHARMACEUTICAL COMPOSITION OF GLP-1/GLP-2 DUAL AGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/039857
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12617
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039857
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/039857 | PHARMACEUTICAL COMPOSITION OF GLP-1/GLP-2 DUAL AGONISTS | Dec 15, 2021 | Pending |
Array
(
[id] => 19497651
[patent_doc_number] => 20240336669
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => NOVEL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/266571
[patent_app_country] => US
[patent_app_date] => 2021-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15788
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266571
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/266571 | NOVEL COMPOUNDS | Dec 9, 2021 | Pending |